NCT00439803View on ClinicalTrials.gov

A Clinical Trial of an Alphavirus Replicon Vaccine for Cytomegalovirus (CMV)

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2008

Conditions
Cytomegalovirus Infections
Interventions
BIOLOGICAL

AVX601

3 doses of AVX601 at 1e7 IU given at T=0, 8, 24 weeks via the IM route

BIOLOGICAL

Placebo

3 doses of placebo given at T=0, 8, 24 weeks via the IM route

BIOLOGICAL

AVX601

3 doses of AVX601 at 1e7 IU given at T=0, 8, 24 weeks via the SC route

BIOLOGICAL

Placebo

3 doses of placebo given at T=0, 8, 24 weeks via the SC route

BIOLOGICAL

AVX601

3 doses of AVX601 at 1e8 IU given at T=0, 8, 24 weeks via the IM route

BIOLOGICAL

AVX601

3 doses of placebo given at T=0, 8, 24 weeks via the IM route

BIOLOGICAL

AVX601

3 doses of AVX601 at 1e8 IU given at T=0, 8, 24 weeks via the SC route

BIOLOGICAL

Placebo

3 doses of placebo given at T=0, 8, 24 weeks via the SC route

Trial Locations (1)

45229

Cincinnati Center for Clinical Research, Cincinnati

Sponsors

Lead Sponsor

AlphaVax, Inc.
All Listed Sponsors
lead

AlphaVax, Inc.

INDUSTRY